Search
Search
About
Log in
Join
Experiences with
Ofatumumab
Posts
Communities
57 public posts
Filter results
New Study for users of Ocrevus or Kesimpta
This study aims to understand changes in MS symptoms between doses for people with MS who are treated with ocrelizumab (Ocrevus) or
ofatumumab
(Kesimpta). We’re conducting this study with the pharmaceutical company Novartis and their consultant STATLOG Inc.
This study aims to understand changes in MS symptoms between doses for people with MS who are treated with ocrelizumab (Ocrevus) or
ofatumumab
(Kesimpta). We’re conducting this study with the pharmaceutical company Novartis and their consultant STATLOG Inc.
BettysMom
in
My MSAA Community
2 months ago
Kesimpta and Pregnancy
A small study follows women who did get pregnant while taking it. https://www.optometryadvisor.com/general-medicine/
ofatumumab
-use-women-relapsing-ms-what-are-the-pregnancy-outcomes/#xd_co_f=ZGZjMWVmMDgtYmZiMi00OTQwLTk4ZDYtMWIxNzE4NmY2NzE5~
A small study follows women who did get pregnant while taking it. https://www.optometryadvisor.com/general-medicine/
ofatumumab
-use-women-relapsing-ms-what-are-the-pregnancy-outcomes/#xd_co_f=ZGZjMWVmMDgtYmZiMi00OTQwLTk4ZDYtMWIxNzE4NmY2NzE5~
CatsandCars
in
My MSAA Community
1 month ago
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD Provided by Clinical Care Options, LLC
In the pivotal studies for patients with R/R CLL, idelalisib was combined with rituximab vs rituximab alone; however, duvelisib was studied as monotherapy vs
ofatumumab
.
In the pivotal studies for patients with R/R CLL, idelalisib was combined with rituximab vs rituximab alone; however, duvelisib was studied as monotherapy vs
ofatumumab
.
lankisterguy
Volunteer
in
CLL Support
1 year ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Rituximab infusion frustration
I’ve been on Rituximab for a few years now (with
ofatumumab
in between before it was pulled in IV form). I always have infusion reactions, even with pre meds! Ugh, it’s so frustrating 😭 I had an infusion Friday and I will say this has by far been the best infusion I’ve had to date.
I’ve been on Rituximab for a few years now (with
ofatumumab
in between before it was pulled in IV form). I always have infusion reactions, even with pre meds! Ugh, it’s so frustrating 😭 I had an infusion Friday and I will say this has by far been the best infusion I’ve had to date.
Jer29-11
in
My MSAA Community
2 years ago
Another infusion/article I found
I was previously on
ofatumumab
IV until the pharmaceutical company discontinued it and only offers it as kesimpta for home sub q injection (for 5x the price 🤔). My doctor was like there’s no way you can do that at home because of your reactions.
I was previously on
ofatumumab
IV until the pharmaceutical company discontinued it and only offers it as kesimpta for home sub q injection (for 5x the price 🤔). My doctor was like there’s no way you can do that at home because of your reactions.
Jer29-11
in
My MSAA Community
3 years ago
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
In addition, they may experience: • Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or
ofatumumab
(Arzerra) In a recent study, ‘individual risk factors associated with a poor prognosis
In addition, they may experience: • Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or
ofatumumab
(Arzerra) In a recent study, ‘individual risk factors associated with a poor prognosis
CLLerinOz
Volunteer
in
CLL Support
2 years ago
Living in the USA with CLL and want to know where to sign up for your COVID-19 Vaccination? A State-by-State List
If you are in treatment, or have had treatment with Rituximab, Obinutuzumab,
Ofatumumab
or other anti-CD20 monoclonal antibodies within the past 6 months, you are less likely to produce an antibody response to a vaccination, but it is expected that you will still develop some T-cell based immunity response
If you are in treatment, or have had treatment with Rituximab, Obinutuzumab,
Ofatumumab
or other anti-CD20 monoclonal antibodies within the past 6 months, you are less likely to produce an antibody response to a vaccination, but it is expected that you will still develop some T-cell based immunity response
AussieNeil
Administrator
in
CLL Support
3 years ago
Newbie here!
My dr switched me to
ofatumumab
infusions, which I know is a pretty new medication. So far, I’m doing well, was able to return back to work a few months after my diagnosis (nurse). I’m just a bit scared for the future!
My dr switched me to
ofatumumab
infusions, which I know is a pretty new medication. So far, I’m doing well, was able to return back to work a few months after my diagnosis (nurse). I’m just a bit scared for the future!
Jer29-11
in
My MSAA Community
4 years ago
New MS DMT
Hello everyone, I found out yesterday about a new DMT called kesimpta (
ofatumumab
). Like Ocrevus it hits the B cell. The difference is its a once a month self administered injection. Im posting a link to the website for those who are interested.
Hello everyone, I found out yesterday about a new DMT called kesimpta (
ofatumumab
). Like Ocrevus it hits the B cell. The difference is its a once a month self administered injection. Im posting a link to the website for those who are interested.
Allen5280
in
My MSAA Community
4 years ago
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Other Type I mAbs include ocrelizumab [OCR] and
ofatumumab
[OFA;]. Type II mAbs such as obinutuzumab (OBZ; Gazyva) and tositumomab (Bexxar) exhibit low CDC activity and lack the ability to localize CD20 into lipid rafts but induce higher levels of direct cell death.
Other Type I mAbs include ocrelizumab [OCR] and
ofatumumab
[OFA;]. Type II mAbs such as obinutuzumab (OBZ; Gazyva) and tositumomab (Bexxar) exhibit low CDC activity and lack the ability to localize CD20 into lipid rafts but induce higher levels of direct cell death.
gardening-girl
in
CLL Support
4 years ago
I was diagnosed 8 years ago today
My previous treatments were Rituxan, in my 10th month after diagnosis, then Idealisib and
Ofatumumab
in a clinical trial, which gave me 39 months of no advancement of disease.
My previous treatments were Rituxan, in my 10th month after diagnosis, then Idealisib and
Ofatumumab
in a clinical trial, which gave me 39 months of no advancement of disease.
KevinCLLITP
in
CLL Support
4 years ago
Ibrutinib and odd side effects
I presume the biggest problems here were caused by
Ofatumumab
, although Zydelig is not a well tolerated drug. I was great for about 39 months until I started having some serious complications and bleeding events and had to have gall bladder removed.
I presume the biggest problems here were caused by
Ofatumumab
, although Zydelig is not a well tolerated drug. I was great for about 39 months until I started having some serious complications and bleeding events and had to have gall bladder removed.
KevinCLLITP
in
CLL Support
5 years ago
Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival (PFS) compared with
ofatumumab
(Arzerra) while producing rapid and durable responses in heavily pretreated patients.
Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival (PFS) compared with
ofatumumab
(Arzerra) while producing rapid and durable responses in heavily pretreated patients.
Jm954
Administrator
in
CLL Support
5 years ago
Pulse Tinnitus
June 2012 Bendamustine and
Ofatumumab
, but changed to Rituxan. 2014 to date IVIG. Jan 2017 Ibrutinib. Trisomy 12 (NOTCH 1 and SF3B1 unmutated), IgVH mutated, ZAP70 -ve, CD38 -ve.
June 2012 Bendamustine and
Ofatumumab
, but changed to Rituxan. 2014 to date IVIG. Jan 2017 Ibrutinib. Trisomy 12 (NOTCH 1 and SF3B1 unmutated), IgVH mutated, ZAP70 -ve, CD38 -ve.
RobertCLL
in
British Tinnitus Association
5 years ago
CLL Tracker - Patient Data
June 2012 Bendamustine and
Ofatumumab
, but changed to Rituxan. 2014 to date IVIG. Jan 2017 Ibrutinib. Trisomy 12 (NOTCH 1 and SF3B1 unmutated), IgVH mutated, ZAP70 -ve, CD38 -ve.
June 2012 Bendamustine and
Ofatumumab
, but changed to Rituxan. 2014 to date IVIG. Jan 2017 Ibrutinib. Trisomy 12 (NOTCH 1 and SF3B1 unmutated), IgVH mutated, ZAP70 -ve, CD38 -ve.
RobertCLL
in
CLL Support
5 years ago
CLL chemo more than 10 days fever!
I have CLL and had my first FCR chemo except not Rituximab but
Ofatumumab
. Everything went well but since 10 days I have extreme high fever 39,9-40 degrees and itchy everywhere on my body and under my feet and hands.
I have CLL and had my first FCR chemo except not Rituximab but
Ofatumumab
. Everything went well but since 10 days I have extreme high fever 39,9-40 degrees and itchy everywhere on my body and under my feet and hands.
Eriksan2
in
CLL Support
5 years ago
Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma
In sub-group analyses, researchers found duvelisib worked just as well as
ofatumumab
among the hardest-to-treat cases, including those patients with p17 deletion or p53 abnormalities, who have few available therapeutic options.
In sub-group analyses, researchers found duvelisib worked just as well as
ofatumumab
among the hardest-to-treat cases, including those patients with p17 deletion or p53 abnormalities, who have few available therapeutic options.
Cllcanada
Top Poster CURE Hero
in
CLL Support
6 years ago
FDA Approves Duvelisib for CLL and Follicular Lymphoma - Sep 24, 2018
Patients were exposed to
ofatumumab
for a median duration of 5 months (range, <0.1 to 6). The ORR was 78% with duvelisib versus 39% with
ofatumumab
. - Len P.S. It seems the drug companies love to choose words that are difficult to pronounce
Copiktra
really???
Patients were exposed to
ofatumumab
for a median duration of 5 months (range, <0.1 to 6). The ORR was 78% with duvelisib versus 39% with
ofatumumab
. - Len P.S. It seems the drug companies love to choose words that are difficult to pronounce
Copiktra
really???
lankisterguy
Volunteer
in
CLL Support
6 years ago
Verastem, with Phase 3 Results, to Request FDA Approve Oral Duvelisib to Treat Advanced CLL and SLL
Verastem’s duvelisib was seen to outperform Arzerra (
ofatumumab
) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced.
Verastem’s duvelisib was seen to outperform Arzerra (
ofatumumab
) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced.
wmay13241
in
CLL Support
7 years ago
Duvelisib Drug Succeeds in Late-Stage Trial
Here is a paragraph from the writeup: "Verastem's drug, Duvelisib, showed a superior progression-free survival rate than the current standard of care, Novartis's Arzerra (
ofatumumab
), when tested on patients suffering from cancers that affect cells of the immune system, Verastem said."
Here is a paragraph from the writeup: "Verastem's drug, Duvelisib, showed a superior progression-free survival rate than the current standard of care, Novartis's Arzerra (
ofatumumab
), when tested on patients suffering from cancers that affect cells of the immune system, Verastem said."
crystalsky
in
CLL Support
7 years ago
1
2
3
Next page
Filter results
Clear filters
Posted in
All communities
CLL Support
50 results
My MSAA Community
6 results
British Tinnitus Association
1 result
Sort by
Most Relevant
Newest